| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AI-generated cancer prevention influencers can target risk groups on social media at low cost
|
Winterstein, Jana T.
|
|
|
217 |
C |
p.
|
artikel
|
| 2 |
Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors
|
Bonnefin, C.
|
|
|
217 |
C |
p.
|
artikel
|
| 3 |
Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer
|
Hong, Tae Hee
|
|
|
217 |
C |
p.
|
artikel
|
| 4 |
Cancers attributed to modifiable factors in Norway 2016–2020
|
Berstad, Paula
|
|
|
217 |
C |
p.
|
artikel
|
| 5 |
Cancer-specific utility instrument for health economic evaluations: A synopsis of the EORTC QLU-C10D user manual and current validity evidence
|
Seyringer, Simone
|
|
|
217 |
C |
p.
|
artikel
|
| 6 |
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
|
Mo, Jeremy
|
|
|
217 |
C |
p.
|
artikel
|
| 7 |
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)
|
Bolek, Hatice
|
|
|
217 |
C |
p.
|
artikel
|
| 8 |
Corrigendum to “Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life” [Eur J Cancer 176 (2022) 88–99]
|
Schulz, Thomas U.
|
|
|
217 |
C |
p.
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
217 |
C |
p.
|
artikel
|
| 10 |
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
|
Tolosa, Pablo
|
|
|
217 |
C |
p.
|
artikel
|
| 11 |
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials
|
Hart, Lowell L.
|
|
|
217 |
C |
p.
|
artikel
|
| 12 |
Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study
|
Wang, Hsin-Yi
|
|
|
217 |
C |
p.
|
artikel
|
| 13 |
Identifying and managing adverse prognosis biomarkers among advanced luminal breast cancer patients: What have we learned?
|
Cottu, Paul
|
|
|
217 |
C |
p.
|
artikel
|
| 14 |
Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results
|
Trama, Annalisa
|
|
|
217 |
C |
p.
|
artikel
|
| 15 |
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
|
Venetis, Konstantinos
|
|
|
217 |
C |
p.
|
artikel
|
| 16 |
Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers
|
Ellebaek, Eva
|
|
|
217 |
C |
p.
|
artikel
|
| 17 |
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial
|
Doyen, Jérôme
|
|
|
217 |
C |
p.
|
artikel
|
| 18 |
Ossifying fibromyxoid tumours: A case series
|
Pozas, Javier
|
|
|
217 |
C |
p.
|
artikel
|
| 19 |
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
|
Pearson, Andrew DJ
|
|
|
217 |
C |
p.
|
artikel
|
| 20 |
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas
|
Foppele, G.F.
|
|
|
217 |
C |
p.
|
artikel
|
| 21 |
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
|
Laktionov, K.
|
|
|
217 |
C |
p.
|
artikel
|
| 22 |
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
|
Dennis, Natalie
|
|
|
217 |
C |
p.
|
artikel
|
| 23 |
Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events
|
Rosnev, Stanislav
|
|
|
217 |
C |
p.
|
artikel
|
| 24 |
Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries
|
Di Carlo, Veronica
|
|
|
217 |
C |
p.
|
artikel
|
| 25 |
Stool eosinophils and immune-related adverse event-enterocolitis
|
Yanagisawa, Satoru
|
|
|
217 |
C |
p.
|
artikel
|
| 26 |
Subgroups varying in risk and density highlight the potential for stratified breast cancer screening
|
Gil Quessep, Eugenio
|
|
|
217 |
C |
p.
|
artikel
|
| 27 |
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022)
|
Pedersen, Sidsel
|
|
|
217 |
C |
p.
|
artikel
|
| 28 |
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
|
Metzger Filho, O.
|
|
|
217 |
C |
p.
|
artikel
|
Tijdschrift beschrijving